市場調査レポート
商品コード
1388221

敗血症診断の世界市場:アッセイ別、原因別、製品別、ラボ別、場所別市場予測 - エグゼクティブコンサルタントガイド付き(2024年~2028年)

Sepsis Diagnostic Markets. Global Market Forecasts by Assay, by Cause, by Product, by Lab, and by Place. With Executive and Consultant Guides. 2024 - 2028

出版日: | 発行: Howe Sound Research | ページ情報: 英文 410 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
敗血症診断の世界市場:アッセイ別、原因別、製品別、ラボ別、場所別市場予測 - エグゼクティブコンサルタントガイド付き(2024年~2028年)
出版日: 2023年10月01日
発行: Howe Sound Research
ページ情報: 英文 410 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

年間4,500万人以上の人々が敗血症に苦しんでいますが、驚くことに決定的な診断法はない状態です。ここ10年で注目されるようになったゲノム・分子診断ツールを駆使しての競争が始まっています。

当レポートは、世界の敗血症診断市場について調査し、市場の概要とともに、アッセイ別、原因別、製品別、ラボ別、場所別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

  • 敗血症診断の概要
  • 市場の定義
  • 調査手法
  • 展望:ヘルスケアとIVD産業

第3章 敗血症電流科学

  • 敗血症とは何か
  • 診断
  • 敗血症の原因
  • 有病率

第4章 業界の概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計装サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関

第5章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測、自動化、診断の動向

第6章 敗血症の診断- 最近の開発

第7章 主要企業の概要

  • Abbott Laboratories
  • Abionic
  • Accel Diagnostics
  • Accelerate Diagnostics
  • ADT Biotech
  • Anatolia Geneworks
  • Axis-Shield Diagnostics Ltd.
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Biocartis
  • BioFire Diagnostics (bioMérieux)
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Cube Dx
  • Curetis N.V./Curetis GmbH
  • Cytovale
  • Deepull Diagnostics
  • DNAe
  • EKF Diagnostics Holdings
  • GeneFluidics
  • GenMark Dx(Roche)
  • Grifols
  • Immunexpress
  • Inflammatix
  • LightDeck Diagnostics
  • Linear Diagnostics
  • Luminex Corp(DiaSorin)
  • Mobidiag(Hologic)
  • NanoDx
  • Nanomix
  • Qiagen
  • Response Biomedical
  • Roche Molecular Diagnostics
  • SeLux Diagnostics
  • Septec
  • Siemens Healthineers
  • Sphingotec
  • T2 Biosystems
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics

第8章 敗血症の世界診断市場の概要

  • 敗血症診断薬- 世界市場概要、国別
  • アッセイ別概要
  • 原因別概要
  • 製品別概要
  • ラボ別概要
  • 場所別概要

第9章 敗血症診断市場、アッセイ別

  • 敗血症診断- 微生物学
  • 敗血症診断-PCR
  • 敗血症診断免疫測定法
  • 敗血症の診断- 感染症その他
  • 敗血症診断用バイオマーカーMDx
  • 敗血症診断用バイオマーカーその他

第10章 世界の敗血症診断市場- 原因別

  • 敗血症の診断- 胃腸
  • 敗血症の診断- 呼吸器系COVID-19
  • 敗血症診断-呼吸器その他
  • 敗血症診断- 新生児
  • 敗血症の診断- その他の原因

第11章 世界の敗血症診断市場- 製品別

  • 敗血症診断- 機器
  • 敗血症診断用消耗品
  • 敗血症診断ソフトウェアとサービス

第12章 世界の敗血症診断市場- ラボ別

  • 敗血症診断ラボ
  • 敗血症診断- ポイントオブケア

第13章 世界の敗血症診断市場- 場所別

  • 敗血症の診断- 病院
  • 敗血症診断- その他

第14章 付録

図表

Table of Tables

  • Table 1: sepsis biomarkers - Established and potential
  • Table 2: Market Players by Type
  • Table 3: Five Factors Driving Growth
  • Table 4: Three Factors Limiting Growth
  • Table 5: Seven Key Diagnostic Laboratory Technology Trends
  • Table 6: - Global Sepsis Diagnostics Market by Country/Region
  • Table 7: Global Market by Assay
  • Table 8: Global Market by Cause
  • Table 9: Global Market by Product
  • Table 10: Global Market by Lab
  • Table 11: Global Market by Place
  • Table 12: Sepsis Diagnostic Microbiology by Country
  • Table 13: Sepsis Diagnostic PCR by Country
  • Table 14: Sepsis Diagnostic Immunoassay by Country
  • Table 15: Sepsis Diagnostic Infectious Disease Other by Country
  • Table 16: Sepsis Diagnostic Biomarker MDx by Country
  • Table 17: Sepsis Diagnostic Biomarker Other by Country
  • Table 18: Sepsis Diagnostic GastroIntestinal by Country
  • Table 19: Sepsis Diagnostic Respiratory COVID-19 by Country
  • Table 20: Sepsis Diagnostic Respiratory Other by Country
  • Table 21: Sepsis Diagnostic Neonatal by Country
  • Table 22: Sepsis Diagnostic Other Cause by Country
  • Table 23: Sepsis Diagnostic Instrumentation by Country
  • Table 24: Sepsis Diagnostic Consumables by Country
  • Table 25: Sepsis Diagnostic Software & Service by Country
  • Table 26: Sepsis Diagnostic In Lab by Country
  • Table 27: Sepsis Diagnostic Point of Care by Country
  • Table 28: Sepsis Diagnostic Hospital by Country
  • Table 29: Sepsis Diagnostic Other Place by Country
  • Table 30: Clinical Lab Fee Schedule
  • Table 31: The Most Common Assays
  • Table 32: Largest Revenue Assays

Table of Figures

  • Figure 1: Sepsis Survival graph
  • Figure 2: Percentage of Sepsis Patients with Comorbidity
  • Figure 3: Global Healthcare Spending
  • Figure 4: The Lab Test Pie
  • Figure 5: Sepsis Clinical Progression
  • Figure 6: The Road to Diagnostics
  • Figure 7: Deaths From Drug Resistant Infections 2050
  • Figure 8: The Changing Age of The World's Population
  • Figure 9: Health Care Consumption by Age
  • Figure 10: Cancer Incidence - Age at Diagnosis
  • Figure 11: Growth in Health Care Spending Developing World
  • Figure 12: Centralized vs. Decentralized Laboratory Service
  • Figure 13: A Highly Multiplexed Syndromic Testing Unit
  • Figure 14: The Real Cost to Sequence the Human Genome
  • Figure 15: The Codevelopment Process
  • Figure 16: Comparing MDx Diagnostic and Traditional Testing
  • Figure 17: Growth rates of Sepsis Diagnostics
  • Figure 18: Global Market Share Chart
  • Figure 19: Sepsis Diagnostics Market Segment Shift Base vs Final year
  • Figure 20: Sepsis Diagnostics Market by Assay Base Year
  • Figure 21: Sepsis Diagnostics Market by Assay Final Year
  • Figure 22: Sepsis Diagnostics Market Segment Shift Base vs Final year
  • Figure 23: Sepsis Diagnostics Market by Cause Base Year
  • Figure 24: Sepsis Diagnostics Market by Cause Final Year
  • Figure 25: Sepsis Diagnostics Market Segment Shift Base vs Final year
  • Figure 26: Sepsis Diagnostics Market by Product Base Year
  • Figure 27: Sepsis Diagnostics Market by Product Final Year
  • Figure 28: Sepsis Diagnostics Market Segment Shift Base vs Final year
  • Figure 29: Sepsis Diagnostics Market by Lab Base Year
  • Figure 30: Sepsis Diagnostics Market by Lab Final Year
  • Figure 31: Sepsis Diagnostics Market Segment Shift Base vs Final year
  • Figure 32: Sepsis Diagnostics Market by Place Base Year
  • Figure 33: Sepsis Diagnostics Market by Place Final Year
  • Figure 34: Sepsis Diagnostic Microbiology Growth
  • Figure 35: Sepsis Diagnostics Syndromic POC Panel Growth
  • Figure 36: Sepsis Diagnostic Immunoassay Growth
  • Figure 37: Sepsis Diagnostic Infectious Disease Other Growth
  • Figure 38: Sepsis Diagnostic Biomarker MDx Growth
  • Figure 39: Sepsis Diagnostic Biomarker Other Growth
  • Figure 40: Sepsis Diagnostic GastroIntestinal Growth
  • Figure 41: Sepsis Diagnostics Respiratory COVID-19
  • Figure 42: Sepsis Diagnostic Respiratory Other Growth
  • Figure 43: Sepsis Diagnostic Neonatal Growth
  • Figure 44: Sepsis Diagnostic Other Cause Growth
  • Figure 45: Sepsis Diagnostic Instrumentation Growth
  • Figure 46: Sepsis Diagnostics Consumables
  • Figure 47: Sepsis Diagnostic Software & Service Growth
  • Figure 48: Sepsis Diagnostic In Lab Growth
  • Figure 49: Sepsis Diagnostics Point of Care
  • Figure 50: Sepsis Diagnostic GastroIntestinal Growth
  • Figure 51: Sepsis Diagnostics Other Place
目次

OVERVIEW:

Over 45 million people a year suffer from sepsis but surprisingly there is no definitive diagnostic. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade.

Will Artificial Intelligence play a role?

It is not clear who will be the winner, but the stakes are global and large. Emergency life saving diagnostics can command a premium price in the market. Understand the different drivers of this huge global diagnostic market and find where the opportunities lie.

Our facts and support = Your success.

The report forecasts the market size out for five years. Growth is coming from the basic factors related to improving levels of health care throughout the world. In addition the legacy of the pandemic has changed the playing field for respiratory infections. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Situation Analysis
  • 1.2. Guide for Executives and Marketing Staff
  • 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

  • 2.1. An Overview of Sepsis Diagnostics
    • 2.1.1. Sepsis the medical emergency
    • 2.1.2. Sepsis Diagnosis and Comorbidity
  • 2.2. Market Definition
    • 2.2.1. Market Size
    • 2.2.2. Currency
    • 2.2.3. Years
    • 2.2.4. Microbiology
    • 2.2.5. PCR
    • 2.2.6. Immunoassay
    • 2.2.7. Other Infectious Disease
    • 2.2.8. Syndromic PoC
    • 2.2.9. Biomarkers Molecular Diagnostics
    • 2.2.10. Biomarkers Other
    • 2.2.11. Limitations
  • 2.3. Methodology
    • 2.3.1. Methodology
    • 2.3.2. Sources
    • 2.3.3. Authors
  • 2.4. Perspective: Healthcare and the IVD Industry
    • 2.4.1. Global Healthcare Spending
    • 2.4.2. Spending on Diagnostics
    • 2.4.3. Important Role of Insurance for Diagnostics

3. Sepsis-Current Science

  • 3.1. What is Sepsis?
    • 3.1.1. Organ Damage
    • 3.1.2. Neonatal sepsis
    • 3.1.3. Prognosis
  • 3.2. Diagnosis
    • 3.2.1. Infection Identification
    • 3.2.2. Biomarkers
    • 3.2.3. Differential diagnosis
    • 3.2.4. The Cytokine Storm-Diagnostic Needs
  • 3.3. Causes of Sepsis
    • 3.3.1. Sepsis Progression
    • 3.3.2. The Cytokine Storm-COVID and Other Situations
  • 3.4. Prevalence
    • 3.4.1. Impact of COVID on Sepsis Prevalence

4. Industry Overview

  • 4.1. Players in a Dynamic Market
    • 4.1.1. Academic Research Lab
    • 4.1.2. Diagnostic Test Developer
    • 4.1.3. Instrumentation Supplier
    • 4.1.4. Chemical/Reagent Supplier
    • 4.1.5. Pathology Supplier
    • 4.1.6. Independent Clinical Laboratory
    • 4.1.7. Public National/regional Laboratory
    • 4.1.8. Hospital Laboratory
    • 4.1.9. Physicians Office Lab (POLS)
    • 4.1.10. Audit Body
    • 4.1.11. Certification Body

5. Market Trends

  • 5.1. Factors Driving Growth
    • 5.1.1. Increasing Prevalence
    • 5.1.2. Antimicrobial Resistance
    • 5.1.3. Artificial Intelligence Impact
    • 5.1.4. Multiplex Diagnostics Impacts
    • 5.1.5. The Aging World
    • 5.1.6. Developing World Impact
  • 5.2. Factors Limiting Growth
    • 5.2.1. The Cost Curve Shrinks the Market
    • 5.2.2. The Diagnostics Dillemma
    • 5.2.3. Adoption Lag and Cost Control
  • 5.3. Instrumentation, Automation and Diagnostic Trends
    • 5.3.1. Traditional Automation and Centralization
    • 5.3.2. The New Automation, Decentralization and Point Of Care
    • 5.3.3. Instruments Key to Market Share
    • 5.3.4. Bioinformatics Plays a Role
    • 5.3.5. PCR Takes Command
    • 5.3.6. Next Generation Sequencing Fuels a Revolution
    • 5.3.7. NGS Impact on Pricing
    • 5.3.8. Whole Genome Sequencing, A Brave New World
    • 5.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
    • 5.3.10. Shifting Role of Diagnostics
    • 5.3.11. The Next Five Years

6. Sepsis Diagnostics - Recent Developments

  • 6.1. Recent Developments-Importance and How to Use This Section
    • 6.1.1. Importance of These Developments
    • 6.1.2. How to Use This Section
  • 6.2. Microplate Dx to Launch UTI Susceptibility Test
  • 6.3. QC for DiaSorin's Luminex Sepsis Tests Cleared
  • 6.4. Cytovale IntelliSep
  • 6.5. Prenosis to Study Sepsis in Acute Care
  • 6.6. DiaSorin Gains CE Mark for Sepsis Assay
  • 6.7. Cytovale to Launch Sepsis Risk-Scoring Test
  • 6.8. Todos Medical to Offer Sepsis PCR Test
  • 6.9. SeptiCyte® RAPID Validated
  • 6.10. Cepheid Group B Strep Test Addresses Neonatal Sepsis
  • 6.11. DeepUll Inks Financing Deal
  • 6.12. Sequencing-Based Approach Shows Promise for Sepsis Dx
  • 6.13. VolitionRx Studies Cancer, Sepsis Tests
  • 6.14. Cytovale Prepping Sepsis Test for FDA Submission
  • 6.15. Great North R & I to Develop POC Sepsis Dx
  • 6.16. Pathogenomix Developing Sepsis Testing Platform
  • 6.17. Gradientech Launches Study of AST System
  • 6.18. Sepsis Test Developers Accelerate Plans
  • 6.19. Immunexpress Receives Clearance for Sepsis Assay
  • 6.20. Prenosis, Roche Partner on Sepsis Detection
  • 6.21. Presymptom Health Developing Test for Sepsis
  • 6.22. Ortho Clinical Diagnostics Interleukin-6 Reagent Pack
  • 6.23. Cytovale to Enter Sepsis Testing Market
  • 6.24. Baebies Awarded $11.6M to Develop Diagnostic Platform to ID Sepsis
  • 6.25. Personalized Medicine in Sepsis
  • 6.26. Point-of-care Device can Diagnose Sepsis in 30 Minutes
  • 6.27. SpeeDx Developing Respiratory Virus Host-Response Test
  • 6.28. Scanogen Developing Blood Infection Test with Sepsis Application
  • 6.29. Inflammatix Developing New Sepsis Dx
  • 6.30. Immunexpress, Biocartis to Roll Out Sepsis Test
  • 6.31. Sepset Biosciences Using COVID-19 Patient Samples to Validate Sepsis Test
  • 6.32. Immunexpress to Develop Sepsis Test
  • 6.33. DNAe Developing POC Sequencing for Sepsis
  • 6.34. NGS technique offers quick, accurate diagnosis of Sepsis
  • 6.35. Portable device diagnoses sepsis faster

7. Profiles of Key Companies

  • 7.1. Abbott Laboratories
  • 7.2. Abionic
  • 7.3. Accel Diagnostics
  • 7.4. Accelerate Diagnostics
  • 7.5. ADT Biotech
  • 7.6. Anatolia Geneworks
  • 7.7. Axis-Shield Diagnostics Ltd.
  • 7.8. Baebies
  • 7.9. Beckman Coulter Diagnostics
  • 7.10. Becton, Dickinson and Company
  • 7.11. Biocartis
  • 7.12. BioFire Diagnostics (bioMérieux)
  • 7.13. bioMérieux Diagnostics
  • 7.14. Bio-Rad Laboratories, Inc.
  • 7.15. Bruker
  • 7.16. Cube Dx
  • 7.17. Curetis N.V. / Curetis GmbH
  • 7.18. Cytovale
  • 7.19. Deepull Diagnostics
  • 7.20. DNAe
  • 7.21. EKF Diagnostics Holdings
  • 7.22. GeneFluidics
  • 7.23. GenMark Dx (Roche)
  • 7.24. Grifols
  • 7.25. Immunexpress
  • 7.26. Inflammatix
  • 7.27. LightDeck Diagnostics
  • 7.28. Linear Diagnostics
  • 7.29. Luminex Corp (DiaSorin)
  • 7.30. Mobidiag (Hologic)
  • 7.31. NanoDx
  • 7.32. Nanomix
  • 7.33. Qiagen
  • 7.34. Response Biomedical
  • 7.35. Roche Molecular Diagnostics
  • 7.36. SeLux Diagnostics
  • 7.37. Septec
  • 7.38. Siemens Healthineers
  • 7.39. Sphingotec
  • 7.40. T2 Biosystems
  • 7.41. Thermo Fisher Scientific Inc.
  • 7.42. Vela Diagnostics

8. Sepsis Global Diagnostic Markets Overview

  • 8.1. Sepsis Diagnostics-Global Market Overview by Country
    • 8.1.1. Table-Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Sepsis Diagnostics Markets Overview by Assay
    • 8.2.1. Table-Global Market by Assay
    • 8.2.2. Chart-Global Market by Assay-Segments Growth
    • 8.2.3. Chart-Global Market by Assay-Share by Year
    • 8.2.4. Chart-Global Market by Assay
    • 8.2.5. Chart-Global Market by Assay-Base Year
    • 8.2.6. Chart-Global Market by Assay-Final Year
  • 8.3. Global Sepsis Diagnostics Markets Overview by Cause
    • 8.3.1. Table-Global Market by Cause
    • 8.3.2. Chart-Global Market by Cause-Segments Growth
    • 8.3.3. Chart-Global Market by Cause-Share by Year
    • 8.3.4. Chart-Global Market by Cause
    • 8.3.5. Chart-Global Market by Cause-Base Year
    • 8.3.6. Chart-Global Market by Cause-Final Year
  • 8.4. Global Sepsis Diagnostics Markets Overview by Product
    • 8.4.1. Table-Global Market by Product
    • 8.4.2. Chart-Global Market by Product-Segments Growth
    • 8.4.3. Chart-Global Market by Product-Share by Year
    • 8.4.4. Chart-Global Market by Product
    • 8.4.5. Chart-Global Market by Product-Base Year
    • 8.4.6. Chart-Global Market by Product-Final Year
  • 8.5. Global Sepsis Diagnostics Markets Overview by Lab
    • 8.5.1. Table-Global Market by Lab
    • 8.5.2. Chart-Global Market by Lab-Segments Growth
    • 8.5.3. Chart-Global Market by Lab-Share by Year
    • 8.5.4. Chart-Global Market by Lab
    • 8.5.5. Chart-Global Market by Lab-Base Year
    • 8.5.6. Chart-Global Market by Lab-Final Year
  • 8.6. Global Sepsis Diagnostics Markets Overview by Place
    • 8.6.1. Table-Global Market by Place
    • 8.6.2. Chart-Global Market by Place-Segments Growth
    • 8.6.3. Chart-Global Market by Place-Share by Year
    • 8.6.4. Chart-Global Market by Place
    • 8.6.5. Chart-Global Market by Place-Base Year
    • 8.6.6. Chart-Global Market by Place-Final Year

9. Sepsis Diagnostic Market-by Assay

  • 9.1. Sepsis Diagnostic - Microbiology
    • 9.1.1. Table Sepsis Diagnostic Microbiology-by Country
    • 9.1.2. Chart - Sepsis Diagnostic Microbiology Growth
  • 9.2. Sepsis Diagnostic - PCR
    • 9.2.1. Table Sepsis Diagnostic PCR-by Country
    • 9.2.2. Chart - Sepsis Diagnostic PCR Growth
  • 9.3. Sepsis Diagnostic-Immunoassay
    • 9.3.1. Table Sepsis Diagnostic Immunoassay-by Country
    • 9.3.2. Chart - Sepsis Diagnostic-Immunoassay Growth
  • 9.4. Sepsis Diagnostic-Infectious Disease Other
    • 9.4.1. Table Sepsis Diagnostic Infectious Disease Other-by Country
    • 9.4.2. Chart - Sepsis Diagnostic-Infectious Disease Other Growth
  • 9.5. Sepsis Diagnostic-Biomarker MDx
    • 9.5.1. Table Sepsis Diagnostic Biomarker MDx-by Country
    • 9.5.2. Chart - Sepsis Diagnostic-Biomarker MDx Growth
  • 9.6. Sepsis Diagnostic-Biomarker Other
    • 9.6.1. Table Sepsis Diagnostic Biomarker Other-by Country
    • 9.6.2. Chart - Sepsis Diagnostic-Biomarker Other Growth

10. Global Sepsis Diagnostics Markets-By Cause

  • 10.1. Sepsis Diagnostic - GastroIntestinal
    • 10.1.1. Table Sepsis Diagnostic GastroIntestinal-by Country
    • 10.1.2. Chart - Sepsis Diagnostic GastroIntestinal Growth
  • 10.2. Sepsis Diagnostic-Respiratory COVID-19
    • 10.2.1. Table Sepsis Diagnostic Respiratory COVID-19- by Country
    • 10.2.2. Chart - Sepsis Diagnostic Respiratory COVID-19
  • 10.3. Sepsis Diagnostic-Respiratory Other
    • 10.3.1. Table Sepsis Diagnostic Respiratory Other-by Country
    • 10.3.2. Chart - Sepsis Diagnostic-Respiratory Other Growth
  • 10.4. Sepsis Diagnostic-Neonatal
    • 10.4.1. Table Sepsis Diagnostic Neonatal-by Country
    • 10.4.2. Chart - Sepsis Diagnostic-Neonatal Growth
  • 10.5. Sepsis Diagnostic-Other Cause
    • 10.5.1. Table Sepsis Diagnostic Other Cause-by Country
    • 10.5.2. Chart - Sepsis Diagnostic-Other Cause Growth

11. Global Sepsis Diagnostics Markets-By Product

  • 11.1. Sepsis Diagnostic - Instrumentation
    • 11.1.1. Table Sepsis Diagnostic Instrumentation-by Country
    • 11.1.2. Chart - Sepsis Diagnostic Instrumentation Growth
  • 11.2. Sepsis Diagnostic-Consumables
    • 11.2.1. Table Sepsis Diagnostic Consumables-by Country
    • 11.2.2. Chart - Sepsis Diagnostic Consumables
  • 11.3. Sepsis Diagnostic-Software & Service
    • 11.3.1. Table Sepsis Diagnostic Software & Service-by Country
    • 11.3.2. Chart - Sepsis Diagnostic-Software & Service Growth

12. Global Sepsis Diagnostics Markets-By Lab

  • 12.1. Sepsis Diagnostic-In Lab
    • 12.1.1. Table Sepsis Diagnostic In Lab-by Country
    • 12.1.2. Chart - Sepsis Diagnostic In Lab Growth
  • 12.2. Sepsis Diagnostic-Point of Care
    • 12.2.1. Table Sepsis Diagnostic Point of Care-by Country
    • 12.2.2. Chart - Sepsis Diagnostic Point of Care

13. Global Sepsis Diagnostics Markets-By Place

  • 13.1. Sepsis Diagnostic - Hospital
    • 13.1.1. Table Sepsis Diagnostic Hospital-by Country
    • 13.1.2. Chart - Sepsis Diagnostic Hospital Growth
  • 13.2. Sepsis Diagnostic-Other Place
    • 13.2.1. Table Sepsis Diagnostic Other Place-by Country
    • 13.2.2. Chart - Sepsis Diagnostic Other Place

14. Appendices

  • 14.1. United States Medicare System: Clinical Laboratory Fees Schedule
  • 14.2. The Most Used IVD Assays
  • 14.3. The Highest Grossing Assays